The latter point is with important clinical relevance, as the GIP/GLP-1 dual receptor agonist tirzepatide improves lipid profiles and cardiovascular risk biomarkers in patients with type 2 diabetes (Wilson et al., 2022; Pirro et al., 2022). The gene discussed is GIP; the disease is type 2 diabetes mellitus.